Onapristone
- Generic Name
- Onapristone
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39NO3
- CAS Number
- 96346-61-1
- Unique Ingredient Identifier
- H6H7G23O3N
- Background
Onapristone has been used in trials studying the treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy.
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Context Therapeutics Inc.
- Registration Number
- NCT06938711
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05618613
- Locations
- ๐บ๐ธ
Cancer Treatment Centers of America - Western Regional Medical Center, Phoenix, Arizona, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
๐บ๐ธCancer Treatment Centers of America - Midwestern Regional Center, Zion, Illinois, United States
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerUnresectable Breast Cancer
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT04872608
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
- Conditions
- Metastatic CancerHER2-negative Breast CancerER-positive Breast Cancer
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 11
- Registration Number
- NCT04738292
- Locations
- ๐บ๐ธ
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
๐บ๐ธMedical College of Wisconsin, Milwaukee, Wisconsin, United States
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
- Conditions
- Refractory Endometrial AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Serous AdenocarcinomaRefractory Endometrial Mixed Cell AdenocarcinomaRefractory Endometrial Undifferentiated CarcinomaRefractory Endometrial Clear Cell AdenocarcinomaRefractory Endometrial Endometrioid Adenocarcinoma
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire AdministrationDiagnostic Test: Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)Diagnostic Test: Progesterone Receptor Positive ( PGR Positive; PR Positive)
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 14
- Registration Number
- NCT04719273
- Locations
- ๐บ๐ธ
Jefferson Abington Hospital, Abington, Pennsylvania, United States
๐บ๐ธThomas Jefferson University, Philadelphia, Pennsylvania, United States
Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 10
- Registration Number
- NCT04142892
- Locations
- ๐ช๐ธ
Hospital Clรญnic de Barcelona, Barcelona, Spain
๐ช๐ธHospital Universitari Vall d'Hebron, Barcelona, Spain
๐ช๐ธHospital Universitario Sant Joan de Reus, Tarragona, Spain
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
- Conditions
- Granulosa Cell Ovarian CancerLow Grade Serous Ovarian/ Primary Peritoneal CancerEndometrioid Endometrial Cancer
- Interventions
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT03909152
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
๐บ๐ธMemorial Sloan Kettering Nassau, Uniondale, New York, United States
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
- Conditions
- Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Arno Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT02052128
- Locations
- ๐ซ๐ท
Institut Curie Oncologie Medicale, Paris, France
๐ซ๐ทCentre Oscar Lambret, Lille, France
๐ซ๐ทInstitut Gustave Roussy, Villejuif, France
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
- Conditions
- Prostate CancerAndrogen-independent Prostate CancerRecurrent Prostate CancerMetastatic Prostate Cancer
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Arno Therapeutics
- Target Recruit Count
- 75
- Registration Number
- NCT02049190
- Locations
- ๐ฌ๐ง
Inst of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.